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In this issue, an interesting report on pediatric hematopoietic stem cell 
transplant activity is presented [1]. The survey involved nine countries of 
Central-East Europe and compared the modification of infrastructures 
(number of centers and number of beds) and activity (number of 
autologous and allogeneic transplants) that occurred between the 
years 2013 and 2018. An increase of 25.9% of transplant activity was 
recorded in the interval time of 5 years, especially in countries such 
as Slovenia, Slovakia, Romania, Poland, and Croatia despite a limited 
increase of new centers or transplant beds. Other countries, such as 
Romania and Ukraine, despite recent improvements, have still an 
insufficient transplant activity compared to their target population.
This study highlights the improvement of Central-East countries in 
achieving the modern standard for hematopoietic cell transplant and 
allows to put the basis for planning the future.
Many thousands of patients underwent hematopoietic stem cell 
transplant every year, the number being increased year by year due 
to the extension of age limit to the elderly and to the multiplication of 
indications [2]. In general, the transplant capacity of each country is 
related to the richness of country (average per capita income), type 
of health assistance (public vs. private vs. mixed system), investment 
in scientific research, and specialist education. Therefore, politics and 
rules can make differences in the same geographical macro-area in 
terms of access to the type of health treatments.
What is the target number of transplant beds that each country should 
plan for the future? Considering the Western European standard of at 
least 30 transplants per million of the population to define a country 
with a high transplant activity, the median annual incidence of pediatric 
cancers of 150 new cases per million of the population under 14 age/
year, and a median length of hospital admission of 50–60 days/
transplant per year, one can forecast a minimum requirement of four 
transplant beds per million of the pediatric population. Moreover, 
hematopoietic stem cell transplant is a complex activity and its success 
relies on a multidisciplinary approach that includes high-quality 
performances for HLA tissue typing, blood banking and pharmacy 
services, cryopreservation and graft manipulation, microbiological and 
imaging diagnostics, and the availability of 24-h medical and nursing 
specialized assistance. All these activities must be well organized and 
subjected to the control of accredited quality health organizations.
Least but not the last, the national and international collaboration within 
registries and scientific associations is fundamental to make public and 
transparent the center activity and to favor the comparison of transplant 
outcomes with other centers.
In conclusion, the transplanted patient is only the spike of an iceberg 
that underlies many hidden but essential tasks. The real challenge 
for the future is to let understand to executives, managers, leaders 
that performing transplant is a way to improve the quality of all health 
systems, either at the local hospital or at a national level.
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